Business
MediPharm Labs Completes First Shipment to France
TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: ...
About this update from Medipharm Labs Corp.
[{"type":"text","content":"MediPharm Labs Completes First Shipment to France\n\n\n\n TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (\"MediPharm\", \"MediPharm Labs\" or the \"Company\"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the completion of the Company's first shipment to France.\n \n\n This milestone follows a production agreement with an international medicinal cannabis organization. This strategic collaboration strengthens MediPharm's position as a trusted supplier of pharmaceutical-grade cannabis products and demonstrates the Company's ability to meet stringent European regulatory standards. The French medicinal cannabis market is projected to experience significant growth over the coming years. Conservative estimates place the market at US$187.6 million by 2025, rising to US$213.3 million by 2030 under current regulatory conditions.\n \n (\n \n\n 1)\n \n\n\n \"MediPharm's completion of our first production order and subsequent shipment to France marks our entry into one of Europe's most promising emerging medical cannabis markets,\" said David Pidduck, CEO of MediPharm Labs. \"This achievement underscores our ability to establish new pathways to market and deliver pharmaceutical-grade products that meet stringent European standards.\"\n \n\n MediPharm Labs continues to expand its global footprint through strategic distribution and pharmaceutical partnerships, leveraging industry-leading licenses from multiple regulatory authorities to access new markets and deliver innovative cannabinoid-based solutions worldwide. As of Q3 2025, international medical cannabis represented 56% of MediPharm's total revenue. The 83% year-over-year growth in revenue for international medical cannabis was achieved through product portfolio expansion across multiple geographies.\n \n\n MediPharm Labs has established distribution and supply partnerships across the globe, and now ships products to 10 countries, underscoring our commitment to advancing global health through trusted, compliant, and high-quality cannabinoid offerings.\n \n\n (1) Statista. (2025).\n \n Medical cannabis market forecast – France\n \n .\n \n https://www.statista.com/outlook/hmo/cannabis/medical-cannabis/france\n \n .\n \n\n\n About MediPharm Labs\n \n\n\n Founded in ...